<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877760</url>
  </required_header>
  <id_info>
    <org_study_id>HBV 09-01</org_study_id>
    <nct_id>NCT00877760</nct_id>
  </id_info>
  <brief_title>Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B</brief_title>
  <acronym>ARES</acronym>
  <official_title>Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a add-on Strategy for the Treatment of HBeAg-positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether it is possible to augment the response of&#xD;
      patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary&#xD;
      peginterferon alpha-2a add-on strategy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined presence of HBV DNA level &lt; 200 IU/mL and HBeAg loss</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>up to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable HBV DNA &lt;60 IU/mL</measure>
    <time_frame>up to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg and HBeAg loss from serum</measure>
    <time_frame>up to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The emergence of HBV polymerase mutations associated with reduced susceptibility to entecavir</measure>
    <time_frame>up to week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained response defined as the combined presence of HBV DNA level &lt; 200 IU/mL and HBeAg loss</measure>
    <time_frame>week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ETV + pegIFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon a-2a</intervention_name>
    <description>180 μg, once per week s.c. for 24 weeks</description>
    <arm_group_label>ETV + pegIFN</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5 mg once daily per os, either 72 weeks or 96 weeks</description>
    <arm_group_label>ETV</arm_group_label>
    <arm_group_label>ETV + pegIFN</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B (HBsAg positive &gt; 6 months)&#xD;
&#xD;
          -  HBeAg positive, anti-HBe negative at screening&#xD;
&#xD;
          -  ALT &gt; 1.3 x ULN within 60 days prior to screening and during screening&#xD;
&#xD;
          -  Liver biopsy performed within 2 years prior to screening or during screening&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Adequate contraception for males and females during treatment and follow up; negative&#xD;
             pregnancy test (for women of childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antiviral therapy against HBV within the previous 6 months&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days of screening&#xD;
&#xD;
          -  Previous treatment with lamivudine or telbivudine for more than six months&#xD;
&#xD;
          -  Severe hepatitis activity as documented by ALT&gt;10 x ULN&#xD;
&#xD;
          -  History of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis,&#xD;
             ascites, bleeding gastric or esophageal varices or encephalopathy)&#xD;
&#xD;
          -  Pre-existent neutropenia (neutrophils &lt; 1,500/mm3) or thrombocytopenia (platelets &lt;&#xD;
             90,000/mm3)&#xD;
&#xD;
          -  Co-infection with hepatitis C virus or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Other acquired or inherited causes of liver disease (i.e. alcoholic liver disease,&#xD;
             obesity induced liver disease, drug related liver disease, auto-immune hepatitis,&#xD;
             hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency)&#xD;
&#xD;
          -  Alpha fetoprotein &gt; 50 ng/ml&#xD;
&#xD;
          -  Hyper- or hypothyroidism (subjects requiring medication to maintain TSH levels in the&#xD;
             normal range are eligible if all other inclusion/exclusion criteria are met)&#xD;
&#xD;
          -  Immune suppressive treatment within the previous 6 months&#xD;
&#xD;
          -  Contra-indications for alpha-interferon therapy like suspected hypersensitivity to&#xD;
             interferon or PEG-interferon or any known pre-existing medical condition that could&#xD;
             interfere with the patient's participation in and completion of the study.&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Other significant medical illness that might interfere with this study: significant&#xD;
             pulmonary dysfunction in the previous 6 months, malignancy other than skin&#xD;
             basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV&#xD;
             positivity, auto-immune diseases, organ transplants other than cornea and hair&#xD;
             transplant)&#xD;
&#xD;
          -  Any medical condition requiring, or likely to require chronic systemic administration&#xD;
             of steroids, during the course of the study&#xD;
&#xD;
          -  Substance abuse, such as alcohol (&gt; 80 g/day), I.V. drugs and inhaled drugs in the&#xD;
             past 2 years.&#xD;
&#xD;
          -  Any other condition which in the opinion of the principal investigator would make the&#xD;
             patient unsuitable for enrollment, or could interfere with the patient participating&#xD;
             in and completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Janssen, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foundation for Liver Research (SLO) and Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhong Shan hospital, Fu Dan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMUMU</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University, Dept of Infections Diseases</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WAMED</name>
      <address>
        <city>Zawiercie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nat. Institute of inf. Disease</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ankara, Medical School</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuksek Ihsitas Hospital, Dept. Gastroenterology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Entecavir pegylated interferon a-2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

